Norgestrienone

Norgestrienone

Clinical data
Synonyms	RU-2010
ATC code	G03AC07 (WHO)
Identifiers
IUPAC name 17α-Ethynylestra-4,9,11-trien-17β-ol-3-one
CAS Number	848-21-5 N
PubChem CID	13313
ChemSpider	12749 Y
UNII	89386PYU9O
KEGG	D07220 Y
ECHA InfoCard	100.011.544
Chemical and physical data
Formula	C20H22O2
Molar mass	294.387 g/mol
3D model (JSmol)	Interactive image
SMILES O=C4\C=C3/C(=C2/C=C\[C@]1([C@@H](CC[C@]1(C#C)O)[C@@H]2CC3)C)CC4
InChI InChI=1S/C20H22O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,8,10,12,17-18,22H,4-7,9,11H2,2H3/t17-,18+,19+,20+/m1/s1 Y Key:GVDMJXQHPUYPHP-FYQPLNBISA-N Y
NY (what is this?)

Norgestrienone (INN) (brand name Ogyline, Planor, Miniplanor; former developmental code name RU-2010), also known as Δ^9,11-norethisterone or 17α-ethynyltrienolone (17α-ethynyltrenbolone), as well as 17α-ethynylestra-4,9,11-trien-17β-ol-3-one, is a steroidal progestin related to norethisterone that is used as a hormonal contraceptive, sometimes in combination with ethinylestradiol. It was developed by Roussel Uclaf and is registered for use only in France. Under the brand name Planor, it is or was marketed in France as 2 mg norgestrienone and 50 μg ethinylestradiol tablets. Norgestrienone has been found to possess similar affinity for the progesterone receptor and androgen receptor, and in accordance, has some androgenic activity. The drug was first described in the literature in 1965.Gestrinone is the 13β-ethyl variant or 18-methyl derivative of norgestrienone.